EP1311484A1 - Derives de biphenyle et leur utilisation comme inhibiteurs de l'integrine - Google Patents

Derives de biphenyle et leur utilisation comme inhibiteurs de l'integrine

Info

Publication number
EP1311484A1
EP1311484A1 EP01969486A EP01969486A EP1311484A1 EP 1311484 A1 EP1311484 A1 EP 1311484A1 EP 01969486 A EP01969486 A EP 01969486A EP 01969486 A EP01969486 A EP 01969486A EP 1311484 A1 EP1311484 A1 EP 1311484A1
Authority
EP
European Patent Office
Prior art keywords
formula
acid
pyridin
compounds
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01969486A
Other languages
German (de)
English (en)
Inventor
Wolfgang Staehle
Simon Goodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1311484A1 publication Critical patent/EP1311484A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Definitions

  • the invention relates to biphenyl derivatives of the formula
  • NHR 7 , -C ( NR 8 ) -NHR 7 , Het 1 -NH or Het 1 ,
  • R H A, cycloalkyl, Ar, arylalkyl or Pol,
  • R 2 , R 3 and R 4 each independently of one another H, A, Hai, NO 2 , OR, N (R) 2 ,
  • R 9 alkyl with 1 to 10 carbon atoms or cycloalkyl with 3 to 15 carbon atoms
  • alkyl with 1 to 8 carbon atoms where the alkyl groups can be substituted one or more times by R 6 and / or their
  • Alkyl carbon chain can be interrupted by -O-, Ar unsubstituted or one, two or three times substituted
  • N atoms which can be unsubstituted or mono- or disubstituted by shark, A, cycloalkyl, OA, O-cycloalkyl, CN, NHA, imino or NO 2 ,
  • Pol is a solid phase without a terminal functional group, m 1, 2, 3 or 4, o 1, 2, 3 or 4, p 1, 2, 3, 4 or 5, and their physiologically acceptable salts and solvates.
  • the object of the invention was to find new compounds with valuable properties, in particular those which are used for the production of medicaments.
  • the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability. Above all, they act as integrin inhibitors, in particular inhibiting the interactions of the ⁇ vß3 or ⁇ vß5 integrin receptors with ligands, such as, for example, the binding of vitronectin to the vß3 integrin receptor.
  • Integrins are membrane-bound, heterodimeric glycoproteins that consist of an ⁇ subunit and a smaller ⁇ subunit. The relative affinity and specificity for ligand binding is determined by combining the various ⁇ and ⁇ subunits.
  • the compounds according to the invention show particular activity in the case of the integrins ⁇ vßl, ⁇ vß3, ⁇ vß ⁇ , ⁇ llbß3 and ⁇ vß ⁇ and ⁇ vß8, preferably of ⁇ vß3, ⁇ vß ⁇ and ⁇ vß ⁇ .
  • potent selective inhibitors of the integrin ⁇ vß3 were found.
  • the ⁇ vß3 integrin is expressed on a number of cells, for example endothelial cells, cells of the smooth vascular muscles, for example the aorta, cells for breaking down bone matrix (osteoclasts) or tumor cells.
  • the action of the compounds according to the invention can e.g. detected using the method developed by J.W. Smith et al. in J. Biol. Chem. 1990, 265, 12267-12271.
  • the dependence of the development of angiogenesis on the interaction between vascular integrins and extracellular matrix proteins is described by P.C. Brooks, R.A. Clark and D.A. Cheresh in Science 1994, 264, 569-571.
  • the compounds of the formula I can inhibit the binding of metalloproteinases to integrins and thus prevent the cells from being able to use the enzymatic activity of the proteinase.
  • An example can be found in the inhibibility of the binding of MMP-2- (matrix metallo-proteinase-2) to the vitronectin receptor ⁇ vß3 by a cyclo-RGD peptide, as described in P.C. Brooks et al., Cell 1996, 85, 683-693.
  • micro-aggregates The spread of tumor cells from a local tumor into the vascular system occurs through the formation of micro-aggregates (microthrombi) through the interaction of the tumor cells with platelets.
  • the tumor cells are shielded by the protection in the micro-aggregate and are not recognized by the cells of the immune system.
  • the micro-aggregates can attach themselves to the vessel walls, which facilitates further penetration of tumor cells into the tissue. Since the formation of the microthrombi is mediated by ligand binding to the corresponding integrin receptors, for example ⁇ vß3 or ⁇ llbß3, on activated platelets, the corresponding antagonists can be regarded as effective metastasis inhibitors.
  • the effect of a compound on an ⁇ vß ⁇ -innate receptor and thus the activity as an inhibitor can be demonstrated, for example, by the method described by JW Smith et al. in J. Biol. Chem. 1990, 265, 12267-12271.
  • the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine, in particular for the prophylaxis and / or therapy of diseases of the circulatory system, thrombosis, heart attack, arteriosclerosis, apoplexy, angina pectoris, tumor diseases such as tumor development or tumor metastasis, osteolytic diseases such as Osteoporosis, pathologically angiogenic diseases such as Inflammation, ophthalmological diseases, diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis, rheumatoid arthritis, osteoarthritis, rubeotic glaucoma, ulcerative colitis, Crohn's disease, atherosclerosis, psoriasis, restenosis after angioplasty, infection, bile sclerosis, infection, biosclerotic infection, multiple infections, bile sclerosis, infection with bile sclerosis, infection with multiple sclerosis Kidney failure and wound healing to support the healing process.
  • ⁇ vß6 is a relatively rare integrin (Busk et al., 1992 J. Biol. Chem. 267 (9), 5790), which is increasingly formed in epithelial tissue during repair processes and preferentially binds the natural matrix molecules fibronectin and tenascin (Wang et al., 1996, Am. J. Respir. Cell Mol. Biol. 15 ( ⁇ ), 664).
  • the physiological and pathological functions of ⁇ vß6 are not yet exactly known, but it is believed that this integrin plays an important role in physiological processes and diseases (e.g. inflammation, wound healing, tumors) in which epithelial cells are involved.
  • ⁇ vß ⁇ is expressed on keratinocytes in wounds (Haapasalmi et al., 1996, J. Invest. Dermatol. 106 (1), 42), from which it can be assumed that in addition to wound healing processes and inflammation, other pathological events of the skin, such as, for example, B. psoriasis Agonists or antagonists of said integrin can be influenced. Furthermore, ⁇ vß ⁇ plays a role in the respiratory epithelium (Weinacker et al., 199 ⁇ , Am. J. Respir. Cell Mol. Biol.
  • ⁇ vßö also plays a role in the intestinal epithelium, so that corresponding integrin agonists / antagonists could be used in the treatment of inflammation, tumors and wounds of the gastrointestinal tract.
  • the compounds of formula I can be used as antimicrobial substances in operations where biomaterials, implants, catheters or pacemakers are used. They have an antiseptic effect.
  • the effectiveness of the antimicrobial activity can be determined by the P. Valentin-Weigund et al. methods described in Infection and Immunity, 1988, 2851-2855.
  • a measure of the absorption of an active pharmaceutical ingredient into an organism is its bioavailability.
  • the organism If the organism is added intravenously, its absolute bioavailability, i.e. the proportion of the drug that remains unchanged in the systemic blood, i.e. gets into the big cycle, at 100%.
  • the active ingredient When a therapeutic active ingredient is administered orally, the active ingredient is usually present as a solid in the formulation and must therefore first dissolve in order for it to overcome the entry barriers, for example the Gastrointestinal tract, the oral mucosa, nasal membranes or the skin, in particular the stratum corneum, can overcome or be absorbed by the body.
  • Data on pharmacokinetics, ie on bioavailability, can be obtained analogously to the method of J. Shaffer et al, J. Pharm. Sciences, 1999, 88, 313-318.
  • Another measure of the resorbability of a therapeutic agent is the logD value, because this value is a measure of the lipophilicity of a molecule.
  • the compounds of formula I have at least one chiral center and can therefore occur in several stereoisomeric forms. All of these forms (e.g. D and L forms) and their mixtures (e.g. the DL forms) are included in the formula.
  • prodrug derivatives are also included in the compounds according to the invention, i.e. with e.g. Alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which are quickly cleaved in the organism to the active compounds of the invention.
  • Solvates of the compounds of the formula I are understood to mean the addition of inert solvent molecules to the compounds of the formula I, which are formed on account of their mutual attraction. Solvates are e.g. Mono- or dihydrates or addition compounds with alcohols, e.g. with methanol or ethanol.
  • the invention relates to the compounds of the formula I and their salts and solvates according to claim 1 and to a process for the preparation of compounds of formula I and their salts and solvates, characterized in that
  • R, R 1 , R 2 , R 3 , o and p have the meanings given in claim 1, but R ⁇ H and in which free hydroxyl or amino groups are present as substituents R 2 or R 3 protected by protective groups, with a compound of formula III
  • R, R 1 , R 2 , R 3 , R 4 , o and p are those specified in claim 1
  • R ⁇ H in which Q is Cl, Br or a reactive esterified OH group and in which free hydroxyl or amino groups are present as substituents R or R 3 protected by protective groups, with a compound of the formula V.
  • R 2 , R 3 , R 4 and / or R 5 into one or more radicals R, R 1 , R 2 , R 3 ,
  • R 4 and / or R 5 converts, for example
  • alkylated a hydroxy group i) hydrolyzed an ester group to a carboxy group, ii) esterified a carboxy group, v) alkylated an amino group, v) an aryl bromide or iodide through a Suzuki coupling with
  • A means alkyl, is linear or branched, and has 1 to 8, preferably 1, 2, 3, 4, 5 or 6 carbon atoms.
  • A is preferably methyl, furthermore ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2 - or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3 - or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl, heptyl or octyl.
  • alkyl groups mentioned which can be substituted one or more times by shark or NO 2 , preferably trifluoromethyl, 2,2,2-trifluoroethyl or 2-nitroethyl, or alkyl groups whose carbon chain is interrupted by -O- can be, preferably -CH 2 -O-CH 3 , -CH 2 -O-CH 2 -CH 3 or -CH 2 -CH 2 -O-CH 3 .
  • Methyl and trifluoromethyl are particularly preferred for A.
  • Ar means unsubstituted or mono-, di- or trisubstituted by A, CF 3 , OH, OA, OCF 3 , CN, NO 2 or shark, where aryl means phenyl, naphthyl, anthryl or biphenylyl. Ar is preferably phenyl or naphthyl which is unsubstituted or mono-, di- or trisubstituted by A, CF 3 , OH, OA, OCF 3 , CN, NO 2 or shark. Ar is particularly preferred phenyl.
  • Arylalkyl also means - (CH 2 ) X -Ar, where Ar has one of the preferred meanings indicated above and where x can be 1, 2 or 3.
  • Arylalkyl is preferably benzyl, phenylethyl or phenylpropyl; benzyl is particularly preferred for arylalkyl.
  • Cycloalkyl with 3 to 15 carbon atoms preferably means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
  • Cycloalkyl also means mono- or bicyclic terpenes, preferably p-menthan, menthol, pinan, bornan or camphor, including any known stereoisomeric form or adamantyl. For campers, this means both L-campers and D-campers.
  • Shark is preferably F, Cl or bromine. Shark F or Cl is particularly preferred.
  • Het is preferably substituted or unsubstituted 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 -Pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or ⁇ -isoxazolyl, 2-, 4- or ⁇ -thiazolyl, 3-, 4- or ⁇ -isothiazolyl, 2-, 3- or 4 -Pyridyl, 2-, 4-, ⁇ - or 6-pyrimidinyl, further preferably 1, 2,3-triazol-1-, -4- or - ⁇ -yl, 1, 2,4-triazol-1-, - 4 or - ⁇ -yl, 1- or ⁇ -tetrazolyl, 1, 2,3-oxadiazol-4- or - ⁇ -yl 1, 2,4-oxadiazol-3- or - ⁇ -yl, 1, 3.4 -Thiadiazol-2- or - ⁇ -y
  • heterocyclic radicals can also be partially or completely hydrogenated.
  • Het can also mean 2,3-dihydro-2-, -3-, -4- or - ⁇ -furyl, 2, ⁇ -dihydro-2-, -3-, -4- or - ⁇ -furyl, tetrahydro -2- or -3-furyl, 1, 3- dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or - ⁇ -pyrrolyl, 2, ⁇ -dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -3-pyrollyl, tetrahydro-1-, -2- or 4-imidazolyl, 2,3-dihydro-1-, -2-, -3-,
  • Het is preferably substituted or unsubstituted 4-pyridyl or 4-benzothiadiazolyl.
  • Het 1 is preferably substituted or unsubstituted 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or ⁇ -imidazolyl, 3-, 4- or 5-pyrazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further preferably 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, ⁇ -, 6- or 7-1 H-indolyl, 1 -, 2-, 4- or ⁇ -benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7 - or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 1-, 4-, ⁇ -, 6-, 7- or 8-phthalazinyl, 2-, 3-, ⁇ -, 6-,
  • Het 1 can also mean 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2, ⁇ -dihydro-1-, -2-, -3-, - 4- or - ⁇ -pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -3-pyrollyl, tetrahydro-1-, -2- or 4-imidazolyl, 2,3-dihydro -1-, -2-, -3-, -4-, -5-, -6-, -7-1H-indolyl, 2,3-dihydro-1-, -2-, -3-, -4 - or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1, 5-dihydro-imidazol-4-one-2- or -5-yl, 1, 4-
  • Het 1 particularly preferably denotes 2-pyridyl or 2-imino-pyridin-1-yl; very particularly preferably 2-imino-pyridin-1-yl.
  • Het 1 -NH is preferably pyrrole-2 or pyrrole-3-ylamino, imidazole-2, imidazole-4 or imidazole- ⁇ -ylamino, pyrazole-3, pyrazole-4 or pyrazole- ⁇ -ylamino, pyridyl -2-, pyridyl-3- or pyridyl-4-ylamino, pyrimidin-2-, pyrimidin-4-, pyrimidin- ⁇ - or pyrimidin-6-ylamino, pyridazin-3- or pyridazin-4-ylamino, pyrazin-2 - or Pyrazin-3-ylamino, where the heterocyclic rings mentioned can be substituted by preferably alkyl.
  • Het 1 -NH is pyridyl-2-ylamino or 4-methyl-pyridin-2-ylamino, very particularly preferably pyridyl-2-ylamino.
  • Pol means a solid phase without a terminal functional group, as explained in more detail below.
  • the term solid phase and resin is used synonymously in the following.
  • the second phenyl radical is preferably coupled in the 3- or 4-position to the first phenyl radical, particularly preferably to the 4-position of the first phenyl ring.
  • the phenylene is preferably substituted in the 1- and 3-positions or in the 1- and 4-positions.
  • Y preferably denotes Het 1 or Het 1 -NH.
  • R 1 represents OR, N (R) 2 , where R has one of the meanings below.
  • R 1 OH is particularly preferred.
  • R represents H, A, cycloalkyl, Ar, arylalkyl or Pol, where A, cycloalkyl, Ar and arylalkyl have one of the meanings described above and Pol has one of the meanings described below.
  • R is particularly preferably Pol or H. R is particularly preferred.
  • R 2 , R 3 and R 4 are each independently H, A, shark, NO 2 , OR, N (R) 2 , CN, CO-R, SO 3 R, SO 2 R, NH-C (O) A or SR, where A and R have one of the meanings described above.
  • R 2 is particularly preferred.
  • R 3 is particularly preferred is shark, A, OA or CN;
  • R 3 is very particularly preferably shark or A.
  • R 4 is preferably H.
  • R 5 denotes H or A, where A has one of the meanings given above. R 5 is particularly preferred.
  • R 6 means shark or NO 2 , where shark has one of the meanings given above.
  • R 6 shark is particularly preferred.
  • R 7 is preferably H, -C (O) R 9 , -C (O) -Ar, R 5 , COOR 9 , COO- (CH 2 ) 0 -Ar, SO 2 -Ar, SO 2 R 9 or SO 2 -Het, where Ar and Het have one of the meanings given above and R 9 is alkyl with 1 to 10 C atoms or cycloalkyl with 3 to 10 C atoms.
  • R 7 is preferably H, methoxycarbonyl, ethoxycarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl.
  • R 8 means CN or NO 2 .
  • m is 1, 2, 3 or 4.
  • m is particularly preferably 2 or 3.
  • o means 1, 2, 3 or 4, particularly preferably 1.
  • p means 1, 2, 3, 4 or 5, particularly preferably 1.
  • the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
  • Some preferred groups of compounds can be expressed by the following sub-formulas la to le, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
  • R means H or A
  • the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I according to claim 1.
  • amino protecting group is generally known and refers to groups which are suitable for protecting (blocking) an amino group against chemical reactions.
  • acyl group is to be understood in the broadest sense in connection with the present process. It encompasses acyl groups derived from aliphatic, araliphatic, alicyclic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and in particular alkoxycarbonyl, alkenyloxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups.
  • acyl groups are alkanoyl such as acetyl, propionyl, butyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as phenoxyacetyl; Alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl; Alkenyloxycarbonyl such as allyloxycarbonyl (aloe), aralkyloxycarbonyl such as CBZ (synonymous with Z), 4-methoxybenzyloxycarbonyl (MOZ), 4-nitrobenzyloxycarbonyl or 9-fluorenylmethoxycarbonyl (Fmoc); 2- (phenylsulfonyl) ethoxycarbonyl; Trimethylsilylethoxycarbonyl (Teo
  • hydroxyl protecting group is also generally known and refers to groups which are suitable for protecting a hydroxyl group against chemical reactions. Typical of such groups are the unsubstituted or substituted aryl, aralkyl, aroyl or acyl groups mentioned above, furthermore also alkyl groups, alkyl, aryl or aralkylsilyl groups or O, O or O, S-acetals.
  • the nature and size of the Hydroxy protective groups are not critical since they are removed again after the desired chemical reaction or reaction sequence; groups with 1-20, in particular 1-10, carbon atoms are preferred.
  • hydroxy protecting groups include aralkyl groups such as benzyl, 4-methoxybenzyl or 2,4-dimethoxybenzyl, aroyl groups such as benzoyl or p-nitrobenzoyl, acyl groups such as acetyl or pivaloyl, p-toluenesulfonyl, alkyl groups such as methyl or tert-butyl, but also allyl, Alkylsilyl groups such as trimethylsilyl (TMS), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS) or triethylsilyl, trimethylsilylethyl, aralkylsilyl groups such as tert.-butyldiphenylsilyl (TBDPS), cyclic acetals such as isopropylidene, cyclo -Methoxybenzyliden- or o, p-Dimethoxy
  • Idenacetal, acyclic acetals such as tetrahydropyranyl (Thp), methoxymethyl (MOM), methoxyethoxymethyl (MEM), benzyloxymethyl (BOM) or methylthiomethyl (MTM).
  • Particularly preferred hydroxy protecting groups are benzyl, acetyl, tert-butyl or TBS.
  • the groups BOC and O-tert-butyl can, for example, preferably be split off with TFA in dichloromethane or with about 3 to ⁇ N HCl in dioxane at 15-30 ° C., the Fmoc group with an about ⁇ to 60% solution of Dimethylamine, diethylamine or piperidine in DMF at 15-30 ° C, the Aloe group can be split gently under precious metal catalysis in chloroform at 20-30 ° C.
  • a preferred catalyst is tetrakis (triphenyl-phosphine) palladium (0).
  • the starting compounds of the formula II to V and 1 to 6 are generally known. If they are new, they can be manufactured according to methods known per se.
  • the compounds of the formula I can also be synthesized on a solid phase, the bond to the solid phase being at R.
  • R 1 also means OPol, NHPol or NRPol, Pol meaning a solid phase without a terminal functional group.
  • Pol stands for the polymeric carrier material as well as for all atoms of the anchor group of a solid phase, except for the terminal functional group.
  • the anchor groups of a solid phase also called linkers, are necessary for the connection of the connection to be functionalized to the solid phase.
  • a summary of solid phase syntheses and the solid phases and / or linkers that can be used for this purpose is given, for example, in Novabiochem - The Combinatorial Chemistry Catalog, March 99, pages S1-S72.
  • the bromophenyl-substituted carboxylic acid 1 is activated in situ by known methods, for example by reaction with diisopropylcarbodiimide, and reacted with the alcohol HO-L, where L has the meaning given above.
  • Subsequent coupling of compound 2 with a (R 3 ) -substituted phenylboronic acid under Suzuki compounds produces the biphenyl derivative 3. Elimination of the protective group SGi under known conditions releases a compound of the formula II.
  • the Suzuki reaction is advantageously carried out in a palladium-mediated manner, preferably by adding Pd (PPh 3 ), in the presence of a base such as potassium carbonate in an inert solvent or solvent mixture, for example DMF, at temperatures between 0 ° and 1 ⁇ 0 °, preferably between 60 ° and 120 °.
  • the reaction time is between a few minutes and several days depending on the conditions used.
  • the boronic acid derivatives can be prepared by conventional methods or are commercially available.
  • the reactions can be carried out analogously to those described in Suzuki et al., J. Am. Chem. Soc. 1989, 111, 314ff. and in Suzuki et al. Chem. Rev. 199 ⁇ , 9 ⁇ , 24 ⁇ 7ff. specified methods are carried out.
  • the invention also relates to the reactive intermediates of the formula III
  • R 4 is H, A, shark, NO 2 , OR, N (F l) 2 , CN, CO-R, S0 3 or SR, m 1, 2, 3 or 4, and their salts and solvates.
  • reaction scheme 2 A in the formulas 3 to 6 has the meanings given above.
  • the hydroxybenzoate of the formula 4 is reacted in the presence of a base according to known reaction conditions for nucleophilic substitution with the dibromo compound Br- (CH 2 ) m -Br, where m has the meaning given in claim 6.
  • the subsequent reaction with 2,2,2-trifluoropyridin-2-yl-acetamide in the presence of a base and the subsequent hydrolysis under the reaction conditions known to the person skilled in the art produces the reactive intermediates of the formula III according to the invention, where Y is Het 1 and Het 1 2-Imino-pyridin-1-yl.
  • Preferred compounds of formula III according to claim 6 are the compounds a) 4- [2- (2-Imino-2H-pyridin-1-yl) ethoxy] benzoic acid and b) 3- [2- (2-imino-2H-pyridin-1-yl) ethoxy] - benzoic acid.
  • the coupling reaction is preferably carried out in the presence of a dehydrating agent, for example a carbodiimide such as dicyclohexylcarbodiimide (DCC), N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (EDC) or diisopropylcarbodiimide (DIC), and furthermore, for example, propanephosphonic anhydride (cf. Chem.
  • a dehydrating agent for example a carbodiimide such as dicyclohexylcarbodiimide (DCC), N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (EDC) or diisopropylcarbodiimide (DIC), and furthermore, for example, propanephosphonic anhydride (cf. Chem.
  • diphenylphosphoryl azide or 2-ethoxy-N-ethoxycarbonyl-1,2-dihydroquinoline in an inert solvent, for example a halogenated hydrocarbon such as dichloromethane, an ether such as tetrahydrofuran or dioxane, an amide such as DMF or Dimethylacetamide, a nitrile such as acetonitrile, in dimethyl sulfoxide or in the presence of these solvents, at temperatures between about -10 and 40, preferably between 0 and 30 °.
  • the reaction time is between a few minutes and several days depending on the conditions used.
  • derivatives of compounds of the formula III preferably a preactivated carboxylic acid, or a carboxylic acid halide, a symmetrical or mixed anhydride or an active ester can also be used.
  • residues for activating the carboxy group in typical acylation reactions are described in the literature (e.g. in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg-Thieme-Verlag, Stuttgart).
  • Activated esters are conveniently formed in situ, e.g. by adding HOBt (1-hydroxybenzotriazole) or N-hydroxysuccinimide.
  • the reaction is usually carried out in an inert solvent, when using a carboxylic acid halide in the presence of an acid-binding agent, preferably an organic base such as triethylamine, dimethylaniline, pyridine or quinoline.
  • an acid-binding agent preferably an organic base such as triethylamine, dimethylaniline, pyridine or quinoline.
  • alkali metal or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali metal or alkaline earth metal preferably of potassium, sodium, calcium or cesium, can also be favorable.
  • reaction conditions for nucleophilic substitutions for example the reaction of a compound IV with a compound of the formula V, are sufficiently known to the person skilled in the art (Lit. Organikum, 17th edition, German Publishing House for Sciences, Berlin 1988).
  • a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert manner Solvents such as ethanol and subsequent evaporation.
  • acids that provide physiologically acceptable salts are suitable for this implementation.
  • inorganic acids can be used, for example sulfuric acid, sulfurous acid, dithionic acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or poly-based carbon.
  • sulfonic or sulfuric acids for example formic acid, acetic acid, propionic acid, hexanoic acid, octanoic acid, decanoic acid, hexadecanoic acid, octadecanoic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid , Isonicotinic acid, methane or ethanesulfonic acid, benzenesulfonic acid, trimethoxybenzoic acid, adamantane carboxylic acid, p-toluenesulfonic acid, glycolic acid, embonic acid, chlorophenoxyacetic acid, aspartic acid, glutamic acid, proline, glyox ylic acid, palmitic acid, par
  • the invention also relates to the compounds of the formula I as claimed in claim 1 and their physiologically acceptable salts or solvates as active pharmaceutical ingredients.
  • the invention furthermore relates to compounds of the formula I as claimed in claim 1 and their physiologically acceptable salts or solvates as integrin inhibitors.
  • the invention also relates to the compounds of the formula I as claimed in claim 1 and their physiologically acceptable salts or solvates for use in combating diseases.
  • the invention further relates to pharmaceutical preparations containing at least one compound of the formula I and / or one of its physiologically acceptable salts or solvates, which are prepared in particular by a non-chemical route.
  • the compounds of the formula I can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active compounds.
  • Suitable carriers are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
  • Tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used for oral use, suppositories for rectal use, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for topical use for parenteral use Ointments, creams or powder.
  • the new compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injectables.
  • the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, taste and / or several other active ingredients, for example one or more vitamins.
  • auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, taste and / or several other active ingredients, for example one or more vitamins.
  • sprays can be used which contain the active ingredient either dissolved or suspended in a propellant gas or propellant gas mixture (for example CO 2 or chlorofluorocarbons).
  • a propellant gas or propellant gas mixture for example CO 2 or chlorofluorocarbons.
  • the active ingredient is expediently used in micronized form, it being possible for one or more additional physiologically compatible solvents to be present, for example ethanol.
  • Inhalation solutions can be administered using standard inhalers.
  • the compounds of formula I and their physiologically acceptable salts or solvates can be used as integrin inhibitors in the control of diseases, in particular thromboses, heart attacks, coronary heart diseases, arterial sclerosis, tumors, osteoporosis, inflammations and infections.
  • the compounds of formula I according to claim 1 and / or their physiologically acceptable salts are also used in pathological processes which are maintained or propagated by angiogenesis, in particular in tumors, restenoses, diabetic retinopathy or rheumatoid arthritis.
  • the substances according to the invention are generally administered in analogy to the compounds described in WO 95/32710, preferably in doses between about 0.05 and 500 mg, in particular between 0.5 and 100 mg per dosage unit.
  • the daily dosage is preferably between about 0.01 and 2 mg / kg body weight.
  • the specific dose for each patient depends on a variety of factors, such as the effectiveness of the special connection used, on age, body weight, general health, gender, on the diet, on the time and route of administration, on the
  • Elimination rate, drug combination and severity of the disease to which the therapy applies are preferred.
  • the compounds of the formula I can be used as integrin ligands for the preparation of columns for affinity chromatography for the purification of integrins.
  • the ligand i.e. a compound of formula I is activated via an anchor function, e.g. the carboxy group, covalently coupled to a polymeric support.
  • Suitable polymeric carrier materials are the polymeric solid phases known per se in peptide chemistry with preferably hydrophilic properties, for example cross-linked poly sugars such as cellulose, Sepharose or Sephadex R , acrylamides, polyethylene glycol-based polymer or tentacle polymers R.
  • the materials for affinity chromatography for integrin purification are produced under conditions which are customary and known per se for the condensation of amino acids.
  • the compounds of the formula I contain one or more chiral centers and can therefore be present in racemic or in optically active form. Racemates obtained can be separated mechanically or chemically into the enantiomers by methods known per se. Diastereomers are preferably formed from the racemic mixture by reaction with an optically active release agent. Suitable release agents are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, Mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as ß-camphorsulfonic acid.
  • optically active acids such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, Mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as ß-camphorsulfonic acid.
  • Enantiomer separation using a column filled with an optically active separating agent is also advantageous; a mixture of hexane / isopropanol / acetonitrile, for example in a volume ratio of 82: 15: 3, is suitable as the mobile phase.
  • an optically active separating agent for example dinitrobenzoyl-phenylglycine
  • optically active compounds of the formula I by the methods described above by using starting materials which are already optically active.
  • customary work-up means: if necessary, water is added, if necessary, depending on the constitution of the end product, the pH is adjusted to between 2 and 10, extracted with ethyl acetate or dichloromethane, and the mixture is dried and dried organic phase over sodium sulfate, evaporates and purifies by chromatography on silica gel, by preparative HPLC and / or by crystallization. The purified compounds are optionally freeze-dried.
  • RT retention time (in minutes) with HPLC in the following systems: Column: Lichrosorb RP Select B 250 x 4 mm 2 .
  • Mass spectrometry (MS) using FAB FAB (Fast Atom Bombardment): MS- FAB (M + H) + , El (M + ) or ESI (M + H) + .
  • the resin "CD” is mixed with 0.5 ml of 4N NaOH, 1 ml of methanol and 4 ml of dioxane.
  • the cleavage solution is neutralized and worked up as usual.
  • 3- (4'-Chlorobiphenyl-4-yl) -3- ⁇ 3- [3- (pyridin-2-ylamino) propoxy] benzoylamino ⁇ propionic acid is obtained.
  • the resin is "AB” with 3-fluoro-phenylboronic acid and then with 4- [3- (pyridin-2-ylamino) propoxyj-benzoic acid [prepared analogously to Example 1 by reacting methyl 4-hydroxybenzoate with 2- (3-hydroxypropylamino) pyridine-N- oxide and reaction with phosphorus trichloride and KOH] implemented.
  • 3- (3'-Fluoro-biphenyl-4-yl) -3- ⁇ 4- [3- (pyridin-2-ylamino) propoxy] benzoylamino-propionic acid is obtained.
  • the resin "DE” (prepared by reaction of 3- (3-bromo-phenyl) -3-tert-butoxycarbonylamino-propionic acid with the solid phase polystyrene A OH (Rapp, Art. No. HA 1 400 00 )]
  • the resin "EF” is mixed with 0.5 ml of 4N NaOH, 1 ml of methanol and 4 ml of dioxane.
  • the cleavage solution is neutralized and worked up as usual.
  • 3- (4'-Chlorobiphenyl-4-yl) -3- ⁇ 4- [2- (2-imino-2H-pyridin-1-yl) ethoxy] benzoylamino ⁇ propionic acid is obtained.
  • Example A Injection glasses
  • a solution of 100 g of an active ingredient of the formula I and ⁇ g of disodium hydrogenphosphate is adjusted to pH 6, ⁇ in 3 l of double-distilled water with 2 N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection jar contains ⁇ mg of active ingredient.
  • Example B Suppositories
  • a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
  • a solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH 2 PO 4 .2H 2 O, 28.48 g of Na 2 HPO 4 .12H 2 O and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
  • Example D ointment
  • a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
  • Example F coated tablets
  • Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
  • Example G capsules
  • a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne de nouveaux dérivés de biphényle de formule générale (I), dans laquelle Y, R, R<1>, R<2>, R<3>, R<4>, m, o et p ont la signification indiquée dans le revendication 1, ainsi que leurs sels ou solvates physiologiquement tolérables. Ces nouveaux composés constituent des inhibiteurs de l'intégrine et peuvent être utilisés pour lutter contre les thromboses, l'infarctus, les coronaropathies, l'artériosclérose, les infections, les tumeurs, l'ostéoporose, les infections et la resténose consécutives à une angioplastie ou être utilisés dans des processus pathologiques qui sont entretenus ou propagés par l'angiogénèse.
EP01969486A 2000-08-23 2001-07-24 Derives de biphenyle et leur utilisation comme inhibiteurs de l'integrine Withdrawn EP1311484A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10041428A DE10041428A1 (de) 2000-08-23 2000-08-23 Biphenylderivate
DE10041428 2000-08-23
PCT/EP2001/008514 WO2002016323A1 (fr) 2000-08-23 2001-07-24 Derives de biphenyle et leur utilisation comme inhibiteurs de l'integrine

Publications (1)

Publication Number Publication Date
EP1311484A1 true EP1311484A1 (fr) 2003-05-21

Family

ID=7653542

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01969486A Withdrawn EP1311484A1 (fr) 2000-08-23 2001-07-24 Derives de biphenyle et leur utilisation comme inhibiteurs de l'integrine

Country Status (17)

Country Link
US (1) US20030187289A1 (fr)
EP (1) EP1311484A1 (fr)
JP (1) JP2004506717A (fr)
KR (1) KR20030022419A (fr)
CN (1) CN1447795A (fr)
AU (1) AU8973201A (fr)
BR (1) BR0113373A (fr)
CA (1) CA2420205A1 (fr)
CZ (1) CZ2003670A3 (fr)
DE (1) DE10041428A1 (fr)
HU (1) HUP0302822A3 (fr)
MX (1) MXPA03001556A (fr)
NO (1) NO20030812L (fr)
PL (1) PL359154A1 (fr)
SK (1) SK2952003A3 (fr)
WO (1) WO2002016323A1 (fr)
ZA (1) ZA200302253B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10127041A1 (de) * 2001-06-02 2002-12-05 Merck Patent Gmbh Integrinantagonisten
JP2019533139A (ja) 2016-09-08 2019-11-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネフローゼ症候群を診断及び処置するための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221227T3 (es) * 1997-11-24 2004-12-16 MERCK &amp; CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
WO1999052879A1 (fr) * 1998-04-14 1999-10-21 American Home Products Corporation Derives d'acylresorcinol inhibiteurs selectifs de la vitronectine
EP0960882A1 (fr) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Acylguanidines de thienyl et leur utilisation comme inhibiteurs de la résorptionosseuse et comme antagonistes du récepteur de la vitronectine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0216323A1 *

Also Published As

Publication number Publication date
KR20030022419A (ko) 2003-03-15
CA2420205A1 (fr) 2003-02-21
AU8973201A (en) 2002-03-04
DE10041428A1 (de) 2002-03-07
SK2952003A3 (en) 2003-06-03
HUP0302822A3 (en) 2004-07-28
JP2004506717A (ja) 2004-03-04
PL359154A1 (en) 2004-08-23
CN1447795A (zh) 2003-10-08
BR0113373A (pt) 2003-07-15
NO20030812D0 (no) 2003-02-21
NO20030812L (no) 2003-02-21
WO2002016323A1 (fr) 2002-02-28
ZA200302253B (en) 2004-06-28
HUP0302822A2 (hu) 2003-12-29
US20030187289A1 (en) 2003-10-02
CZ2003670A3 (cs) 2003-06-18
MXPA03001556A (es) 2003-06-06

Similar Documents

Publication Publication Date Title
DE10112771A1 (de) Inhibitoren des Integrins alpha¶v¶beta¶6¶
DE10006139A1 (de) Indol-3-yl-Derivate
EP1124824B1 (fr) Derives de chromenone et de chromanone utilises comme inhibiteurs d&#39;integrine
DE60105192T2 (de) Harnstoff- und urethanderivate als integrin inhibitoren
EP1472224B1 (fr) 3-alkanoylamino-acide propionique dérivés utilisés comme inhibiteurs de l&#39;intégrine avss6
DE60311578T2 (de) Inhibitoren der gpib-vwf wechselwirkung
EP1153014B1 (fr) Derives de la beta-alanine
WO2002016328A1 (fr) Derives de biphenyle et leur utilisation en tant qu&#39;inhibiteurs d&#39;integrine
EP1290010A1 (fr) Pyridin-2-yl-aminoalkylcarbonylglycyl-$g(b)-alanine et ses derives
DE19713000A1 (de) Adhäsionsrezeptor-Antagonisten
EP1194401B1 (fr) Derives de diacylhydrazine
EP1480971A1 (fr) Derives d&#39;isoquinoleine
DE10118550A1 (de) Liganden des Integrins alpha¶nu¶beta¶6¶
EP1311484A1 (fr) Derives de biphenyle et leur utilisation comme inhibiteurs de l&#39;integrine
EP1392654A1 (fr) Antagonistes d&#39;integrine
WO2003014088A1 (fr) Thioamides de biphenyle comme antagonistes de recepteurs de l&#39;integrine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021221

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050201